Viridian Therapeutics Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Steve Mahoney

Chief Executive Officer (CEO)

US$13.0m

Compensación total

Porcentaje del salario del CEO	0.9%
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	3.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Steve Mahoney en comparación con los beneficios de Viridian Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$218m
Dec 31 2023	US$13m	US$113k	-US$238m

Compensación vs. Mercado: La compensación total de Steve($USD13.02M) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD1.33M).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Steve con los resultados de la empresa.

CEO

Steve Mahoney (53 yo)

less than a year

Permanencia

US$13,022,654

Compensación

Mr. Stephen F. Mahoney, also known as Steve, J. D. serves as President, CEO & Director at Viridian Therapeutics, Inc. since October 30, 2023. He served as President, Chief Financial and Operating Officer a...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Stephen Mahoney	CEO, President & Director	less than a year	US$13.02m	sin datos
Seth Harmon	Senior VP of Finance and Accounting	less than a year	US$6.67m	0.0016% $ 12.2k
Thomas Beetham	Chief Operating Officer	less than a year	US$5.17m	sin datos
Eric Olson	Co-Founder & Chairman of Scientific Advisory Board	no data	sin datos	sin datos
Michael Bristow	Co-Founder & Member of the Scientific Advisory Board	no data	sin datos	sin datos
Marvin Caruthers	Co-Founder & Scientific Advisory Board Member	no data	sin datos	sin datos
Vahe Bedian	Co-Founder & Scientific Advisor	no data	sin datos	sin datos
Jennifer Tousignant	Chief Legal Officer	less than a year	sin datos	sin datos
John Jordan	Vice President of Investor Relations & Corporate Communications	no data	sin datos	sin datos
Anthony Casciano	Chief Commercial Officer	1.2yrs	sin datos	sin datos
Thomas Ciulla	Chief Medical Officer	1.4yrs	sin datos	0.0012% $ 9.2k
Shan Wu	Chief Business Officer	less than a year	sin datos	sin datos

0.7yrs

Permanencia media

53.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0K1R no se considera experimentado ( 0.5 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Stephen Mahoney	CEO, President & Director	less than a year	US$13.02m	sin datos
Eric Olson	Co-Founder & Chairman of Scientific Advisory Board	no data	sin datos	sin datos
Michael Bristow	Co-Founder & Member of the Scientific Advisory Board	no data	sin datos	sin datos
Marvin Caruthers	Co-Founder & Scientific Advisory Board Member	no data	sin datos	sin datos
Arlene Morris	Independent Director	6.4yrs	US$477.83k	0% $ 0
Victor Ambros	Scientific Advisory Board Member	no data	sin datos	sin datos
Stefanie Dimmeler	Scientific Advisory Board Member	no data	sin datos	sin datos
Jeffery Molkentin	Scientific Advisory Board Member	no data	sin datos	sin datos
Eva van Rooij	Scientific Advisory Board Member	no data	sin datos	sin datos
Tomas Kiselak	Independent Chairperson of Board	3.7yrs	US$503.83k	0% $ 0
Jennifer Moses	Independent Director	2.9yrs	US$467.83k	0% $ 0
Peter Harwin	Independent Director	3.7yrs	US$471.83k	0% $ 0

3.7yrs

Permanencia media

53yo

Promedio de edad

Junta con experiencia: La junta directiva de 0K1R se considera experimentada (3.5 años de antigüedad promedio).

Viridian Therapeutics Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. Announces Executive Changes

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Viridian Therapeutics, Inc. Announces Resignation of Kristian Humer as Chief Financial Officer

Recent updates

First quarter 2024 earnings released: US$0.79 loss per share (vs US$1.61 loss in 1Q 2023)

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

New major risk - Shareholder dilution

Full year 2023 earnings released: US$5.31 loss per share (vs US$4.05 loss in FY 2022)

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

Viridian Therapeutics, Inc. Announces Executive Changes

Third quarter 2023 earnings released: US$1.09 loss per share (vs US$0.86 loss in 3Q 2022)

Viridian Therapeutics, Inc. announced that it has received $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Viridian Therapeutics, Inc. announced that it expects to receive $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Viridian Therapeutics, Inc. Announces Resignation of Kristian Humer as Chief Financial Officer

Viridian Therapeutics, Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$1.27 loss per share (vs US$1.06 loss in 2Q 2022)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

First quarter 2023 earnings released: US$1.61 loss per share (vs US$0.98 loss in 1Q 2022)

President recently bought US$101k worth of stock

President recently bought US$160k worth of stock

Full year 2022 earnings released: US$4.05 loss per share (vs US$6.66 loss in FY 2021)

High number of new and inexperienced directors

Viridian Therapeutics, Inc. Appoints Scott Myers as Chief Executive Officer

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (Ted)

High number of new and inexperienced directors

Viridian Therapeutics Announces First Patient Enrolled in the ‘Thrive’ Phase 3 Trial in Patients with Thyroid Eye Disease

Third quarter 2022 earnings released: US$0.86 loss per share (vs US$1.26 loss in 3Q 2021)

High number of new and inexperienced directors

Viridian Therapeutics, Inc Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Viridian Therapeutics, Inc. Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting

High number of new and inexperienced directors

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$2.22 loss in 2Q 2021)

Viridian Therapeutics, Inc. Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

High number of new and inexperienced directors

Viridian Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

High number of new and inexperienced directors

Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer

Viridian Therapeutics, Inc. to Report Q1, 2022 Results on May 12, 2022

High number of new and inexperienced directors

Viridian Therapeutics, Inc. announced that it expects to receive $75 million in funding from Hercules Capital, Inc.

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

High number of new and inexperienced directors

Viridian Therapeutics, Inc. to Report Q4, 2021 Results on Mar 10, 2022

High number of new and inexperienced directors

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration

Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)

High number of new and inexperienced directors

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad